Clinical Trial

Morning Versus Bedtime Dosing of Antihypertensive Medication

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently. The investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-10-13.
Trial Details
NCT Number NCT05089448
Lead Sponsor Yan Li
Conditions Hypertension, Blood Pressure, Drug Use
Enrollment 300 participants
Start Date 2021-01-28
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-06